Zobrazeno 1 - 10
of 2 021
pro vyhledávání: '"P. Goadsby"'
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 7, Pp 1654-1668 (2024)
Abstract Objective Migraine is a complex and disabling neurological disorder. Recent years have witnessed the development and emergence of novel treatments for the condition, namely those targeting calcitonin gene‐related peptide (CGRP). However, t
Externí odkaz:
https://doaj.org/article/0f1ae891d172448aadba1af2f2f5ad8e
Autor:
Robyn-Jenia Wilcha, Peter J. Goadsby
Publikováno v:
Cephalalgia Reports, Vol 7 (2024)
Background Verapamil is recommended as a first-line preventive for episodic and chronic cluster headache, however, its use is limited by a wide range of adverse events. From clinical practice at a tertiary headache centre, we have observed that the i
Externí odkaz:
https://doaj.org/article/94ad8e7768c54c09827361cd8924cd0c
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Medication-overuse headache (MOH), which potentially involves 1–2% of the population, is defined as a headache, on ≥ 15 days a month affected, along with overuse of one or other acute attack medications. MOH presents with significant cha
Externí odkaz:
https://doaj.org/article/4a9cce3ecd8d45f9937e4c614fc7cfff
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-16 (2024)
Abstract Background Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migrai
Externí odkaz:
https://doaj.org/article/fca3cd0fb19d4594a041cd2b7b168b47
Autor:
Linus Jönsson, Susanne F. Awad, Stephane A. Regnier, Brian Talon, Steven Kymes, Xin Ying Lee, Peter J. Goadsby
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality of life (HRQoL) improvement beyond improvements in monthly migraine day (MMD) reduction. Investigations into the co
Externí odkaz:
https://doaj.org/article/7abee575dccc432ea565d608deb6bddf
Autor:
Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby
Publikováno v:
Neurology and Therapy, Vol 13, Iss 1, Pp 85-105 (2023)
Abstract Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. Reported are the results from the first head-to-head study of two CGRP anta
Externí odkaz:
https://doaj.org/article/fa1cedafce0740f8a2e9f005177a71b3
Autor:
Gloria Vaghi, Roberto De Icco, Cristina Tassorelli, Peter J. Goadsby, Teófila Vicente-Herrero, Elena Ruiz de la Torre
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Migraine is a highly prevalent primary headache disorder and a leading cause of disability. Difficulties in access to care during diagnostic and therapeutic journey contribute to the disease burden. Several target-specific drugs h
Externí odkaz:
https://doaj.org/article/fc2e21002f344c7fbfbb8cafee2bc340
Autor:
Nazia Karsan, Peter J. Goadsby
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background The premonitory phase, or prodrome, of migraine, provides valuable opportunities to study attack initiation and for treating the attack before headache starts. Much that has been learned about this phase in recent times has come f
Externí odkaz:
https://doaj.org/article/fc123fe88b1c4ee28b5cd8a66dadb3cb
Autor:
Linda Al-Hassany, Nazia Karsan, Christian Lampl, Peter J. Goadsby, Antoinette MaassenVanDenBrink
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-5 (2023)
Abstract Migraine is a debilitating disorder, and while the introduction of monoclonal antibodies (mAbs) has led to efficacious and tolerable responses, a substantial number of patients are so-called “non-responders”. We introduce reasons for thi
Externí odkaz:
https://doaj.org/article/86103238d77b436aae4d961c4da1e0c8
Publikováno v:
Cephalalgia Reports, Vol 7 (2024)
Background: Indomethacin is a non-steroidal anti-inflammatory used to diagnose and treat hemicrania continua and paroxysmal hemicrania. Treatment can be complicated by gastrointestinal adverse effects; less commonly reported are idiosyncratic neurops
Externí odkaz:
https://doaj.org/article/db50bb229a86408c99bcc63bea0a38bd